A University of Michigan team describes distinct androgen receptor effects for compounds depending on their DNA response element interactions in prostate cancer. Using a combination of high-throughput drug screening, fluorescent reporter plasmids, transcriptomics, chromatin immunoprecipitation assays, and other approaches, the researchers screened thousands of compounds, searching for those that curbed cancer growth but spared growth by normal cells.